(Q41931691)

English

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

scientific article published on January 1997

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Punt CJ

1

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Voest EE

2

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Tueni E

3

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Van Oosterom AT

4

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Backx A

5

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

De Mulder PH

6

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Hecquet B

7

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Lucas C

8

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Gerard B

9

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Bleiberg H

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

language of work or name

0 references

publication date

1 January 1997

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

76

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

1376-1381

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Clinical trials of agents that reverse multidrug resistance. A literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Constitutive expression of multidrug resistance in human colorectal tumours and cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Long QT: Good, bad or indifferent?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

5 June 2018

Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228136

18 August 2018

In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

QT interval prolongation associated with anthracycline cardiotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of a multidrug resistance gene in human cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/9374386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1997.563

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41931691&oldid=2204869194"